Nola Hylton

2.2k total citations
25 papers, 1.3k citations indexed

About

Nola Hylton is a scholar working on Radiology, Nuclear Medicine and Imaging, Cancer Research and Oncology. According to data from OpenAlex, Nola Hylton has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Radiology, Nuclear Medicine and Imaging, 12 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in Nola Hylton's work include MRI in cancer diagnosis (11 papers), Breast Cancer Treatment Studies (9 papers) and Radiomics and Machine Learning in Medical Imaging (8 papers). Nola Hylton is often cited by papers focused on MRI in cancer diagnosis (11 papers), Breast Cancer Treatment Studies (9 papers) and Radiomics and Machine Learning in Medical Imaging (8 papers). Nola Hylton collaborates with scholars based in United States, Canada and Switzerland. Nola Hylton's co-authors include Constance D. Lehman, Paul T. Weatherall, Constantine Gatsonis, Stuart J. Schnitt, Jeffrey D. Blume, Mitchell D. Schnall, Etta D. Pisano, David Thickman, Laura J. Esserman and Ellen Warner and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Nola Hylton

22 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nola Hylton United States	9	700	475	454	371	142	25	1.3k
In-Ae Park South Korea	24	627 0.9×	509 1.1×	476 1.0×	241 0.6×	109 0.8×	66	1.5k
Corrado Tinterri Italy	18	256 0.4×	621 1.3×	318 0.7×	487 1.3×	189 1.3×	79	1.1k
Rosalind P. Candelaria United States	16	309 0.4×	795 1.7×	657 1.4×	325 0.9×	98 0.7×	51	1.2k
R. Schulz-Wendtland Germany	16	423 0.6×	434 0.9×	350 0.8×	357 1.0×	381 2.7×	65	1.2k
Eleanor Cornford United Kingdom	17	221 0.3×	410 0.9×	351 0.8×	253 0.7×	243 1.7×	38	874
Andrea Sagona Italy	14	215 0.3×	418 0.9×	258 0.6×	206 0.6×	108 0.8×	41	708
Paula H.M. Elkhuizen Netherlands	27	486 0.7×	1.3k 2.7×	601 1.3×	500 1.3×	255 1.8×	55	1.7k
A. Magener Germany	13	365 0.5×	235 0.5×	203 0.4×	294 0.8×	131 0.9×	24	920
Marion E. Scoggins United States	14	175 0.3×	317 0.7×	229 0.5×	277 0.7×	120 0.8×	36	653
Cynthia Aparecida Bueno de Toledo Osório Brazil	18	178 0.3×	311 0.7×	146 0.3×	260 0.7×	110 0.8×	49	786

Countries citing papers authored by Nola Hylton

Since Specialization

Citations

This map shows the geographic impact of Nola Hylton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nola Hylton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nola Hylton more than expected).

Fields of papers citing papers by Nola Hylton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nola Hylton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nola Hylton. The network helps show where Nola Hylton may publish in the future.

Co-authorship network of co-authors of Nola Hylton

This figure shows the co-authorship network connecting the top 25 collaborators of Nola Hylton. A scholar is included among the top collaborators of Nola Hylton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nola Hylton. Nola Hylton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meisel, Jane, Katia Khoury, A. Jo Chien, et al.. (2024). Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA509–LBA509. 4 indexed citations

Trivedi, Meghna S., Rebecca Shatsky, Rita Nanda, et al.. (2024). LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial. Annals of Oncology. 35. S1208–S1209. 1 indexed citations

Onishi, Natsuko, Wen Li, Elissa R. Price, et al.. (2024). Prospective performance of an MRI algorithm for early re-direction of breast cancer neoadjuvant treatment. Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition.

Chien, A. Jo, Kevin Kalinsky, Rita A. Mukhtar, et al.. (2022). Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer. Cancer Research. 82(4_Supplement). OT1–10. 2 indexed citations

Tran, Geraldine, Wen Li, David Newitt, et al.. (2021). Abstract PD6-08: DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy. Cancer Research. 81(4_Supplement). PD6–8. 1 indexed citations

Magbanua, Mark Jesus M., Wen Li, Denise M. Wolf, et al.. (2020). Abstract A50: Circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) for monitoring and predicting response to neoadjuvant therapy (NAT) in high-risk early breast cancer patients in the I-SPY 2 TRIAL. Clinical Cancer Research. 26(11_Supplement). A50–A50. 1 indexed citations

Duong, Stephanie Q., Jacob B. Allred, Dorota J. Wisner, et al.. (2018). Abstract GS5-05: Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) CALGB 40903 (Alliance). Cancer Research. 78(4_Supplement). GS5–5. 5 indexed citations

Nanda, Rita, Minetta C. Liu, Christina Yau, et al.. (2017). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.. Journal of Clinical Oncology. 35(15_suppl). 506–506. 158 indexed citations

Li, Wen, Vignesh A. Arasu, David Newitt, et al.. (2016). Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography. 2(4). 378–387. 17 indexed citations

10.

Fournier, Marcia V., Alan Derr, Kevin Reid, et al.. (2015). Abstract P3-06-19: Gene expression profiles accompanying phenotypic changes during non-malignant breast epithelial cells acini formation to explain MRI phenotypes. Cancer Research. 75(9_Supplement). P3–6. 1 indexed citations

11.

Rugo, HS, O. Olopade, Angela DeMichele, et al.. (2013). Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL. Cancer Research. 73(24_Supplement). S5–2. 48 indexed citations

12.

Mukhtar, Rita A., Christina Yau, Mark Rosen, et al.. (2013). Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Annals of Surgical Oncology. 20(12). 3823–3830. 74 indexed citations

13.

Fumagalli, Debora, Philippe L. Bédard, Zeina Nahleh, et al.. (2012). A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. The Lancet Oncology. 13(6). e240–e248. 52 indexed citations

14.

DeMichele, A., Marc E. Lenburg, Joe W. Gray, et al.. (2009). Neoadjuvant Response in the Context of a Biologically Defined Low or High Risk Tumor Has a Different Clinical Consequence, the I-SPY Trial (CALGB 150007/150012, ACRIN 6657).. Cancer Research. 69(24_Supplement). 2003–2003. 1 indexed citations

15.

Schnall, Mitchell D., Jeffrey D. Blume, David A. Bluemke, et al.. (2006). Diagnostic Architectural and Dynamic Features at Breast MR. 2 indexed citations

16.

Schnall, Mitchell D., Jeffrey D. Blume, David A. Bluemke, et al.. (2006). Diagnostic Architectural and Dynamic Features at Breast MR Imaging: Multicenter Study. Radiology. 238(1). 42–53. 390 indexed citations

17.

Shah, Natasha, Jessica Gibbs, Dulcy Wolverton, et al.. (2005). Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. Journal of Biomedical Optics. 10(5). 51503–51503. 50 indexed citations

18.

Lehman, Constance D., Jeffrey D. Blume, Paul T. Weatherall, et al.. (2005). Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 103(9). 1898–1905. 290 indexed citations

19.

Esserman, L., et al.. (2002). Method for quantitative assessment of tumor volume response to neoadjuvant chemotherapy using MRI. 3. 1645–1647. 1 indexed citations

20.

Esserman, Laura J., Dulcy Wolverton, & Nola Hylton. (2000). Integration of breast imaging into cancer management. Current Oncology Reports. 2(6). 572–581. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact